Human CCR8 Full Length Protein (VLP)
分子別名（Synonym）
CCR8,CD198,ChemR1,CKRL1,TER-1
表達區(qū)間及表達系統(tǒng)（Source）
Human CCR8 Full Length Protein-VLP (CC8-H52P4) is expressed from human 293 cells (HEK293). It contains AA Asp 2 - Leu 355 (Accession # P51685-1).
Predicted N-terminus: Asp
蛋白結(jié)構(gòu)（Molecular Characterization）
The protein has a calculated MW of 44.6 kDa | 56.1 kDa.
Virus-like particles(VLPs) are formed by self-assembly of envelop/capsid proteins from viruses. Membrane Proteins can be constituted in-situ with VLPs produced from HEK293 cell cultures. These VLPs concentrate conformationally intact membrane proteins directly on the cell surface and produce soluble, high-concentration proteins perfect for immunization and antibody screening.
The VLPs provide the display of properly folded membrane proteins in their native cellular membrane in a compact size of 100~300 nm diameter (similar to the size of most viruses) making it optimal targets for dendritic cells in vivo and surface attachment for phage display.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
制劑（Formulation）
The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).
Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
運輸（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存儲（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 12 months under sterile conditions.
背景（Background）
CC趨化因子受體8（CCR8），主要在淋巴組織中表達，也在腎小球足細胞和人臍靜脈內(nèi)皮細胞（HUVEC）中發(fā)現(xiàn)。CCR8與Th2淋巴細胞有關(guān)，Th2淋巴細胞對過敏至關(guān)重要，在淋巴細胞活化、遷移、增殖和分化以及過敏性疾病中起著重要作用。CCR8與CCL1（也稱為I-309）和CCL16（也稱為肝臟表達的趨化因子）結(jié)合。它還對病毒來源的三種趨化因子：vMIP-I、vMIP-II和vMCC-I表現(xiàn)出高親和力。
關(guān)鍵字： CCR8;CCR8蛋白;CCR8重組蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。